Welcome to our dedicated page for Kalaris Therapeutics news (Ticker: KLRS), a resource for investors and traders seeking the latest updates and insights on Kalaris Therapeutics stock.
Kalaris Therapeutics, Inc. (NASDAQ: KLRS) is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for prevalent retinal diseases, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). News about Kalaris often centers on the progress of its lead investigational therapy, TH103, a fully humanized recombinant fusion protein designed as an anti-VEGF decoy receptor with features intended to enhance VEGF inhibition and intraocular retention.
Investors and observers following KLRS news can expect regular updates on the TH103 clinical program. These include announcements of enrollment and design changes for Phase 1 and Phase 1b/2 trials in treatment-naïve nAMD patients, initial safety, pharmacokinetic, and preliminary efficacy data, and company commentary on how early clinical findings align with TH103’s molecular design and preclinical profile. Kalaris also issues news releases when it presents data or corporate overviews at healthcare and emerging growth equity conferences.
Another recurring theme in Kalaris news is corporate and financial development. The company reports quarterly financial results, highlighting research and development spending, cash and investment balances, and runway expectations based on its operating plans. It also discloses leadership changes, such as the appointment of senior clinical and financial executives, and capital-raising activities like private placements of common stock and pre-funded warrants with institutional investors.
This KLRS news page aggregates these company communications, providing a centralized view of clinical milestones, financing transactions, governance updates, and investor events related to Kalaris Therapeutics’ efforts to advance TH103 and its broader retinal disease program.
Kalaris Therapeutics (NASDAQ: KLRS) entered a securities purchase agreement for an oversubscribed private placement to raise approximately $50.0 million gross, expected to close on or about December 19, 2025.
The financing consists of 4,200,000 common shares at $10.00 per share and 800,000 pre-funded warrants at $9.9999 each (exercise price $0.0001), with resale registration rights to be filed with the SEC. Morgan Stanley, Leerink Partners, and William Blair act as placement agents.
Based on current plans, management expects the net proceeds plus existing cash will fund operations into the third quarter of 2027, and proceeds will advance clinical development of TH103 for neovascular AMD and for general corporate purposes.
Kalaris Therapeutics (NASDAQ: KLRS) reported positive initial Phase 1a single ascending dose data for TH103 in treatment‑naïve neovascular AMD (N=13) with three dose levels (0.5 mg, 1.5 mg, 2.5 mg) and 6 months follow‑up. Key outcomes at Month 1 included a mean +10‑letter BCVA, −129 μm central subfield thickness (CST), and ~95% reduction in central intraretinal fluid. Pharmacokinetics showed dose‑adjusted plasma Cmax 27–51‑fold lower versus current leading agents. After one injection, 31% of patients required no additional anti‑VEGF treatment through 6 months. Two transient cases of intraocular inflammation at 2.5 mg were attributed to host cell protein; manufacturing was updated and no new IOI cases were seen with purified material. Kalaris is accelerating its Phase 1b/2 multi‑ascending dose study and expects preliminary data in 2H 2026. Conference call/webcast held today at 4:30 PM ET.
Kalaris Therapeutics (Nasdaq: KLRS) announced that management will present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference.
Presentation details: Matthew Feinsod, Chief Medical Officer, will present on Wednesday, December 3, 2025 from 11:30–11:55 AM ET at Florida Atlantic University in Boca Raton, FL. Management will be available for one-on-one meetings by arrangement with conference representatives.
Kalaris (Nasdaq: KLRS) reported Q3 2025 results and business updates on Nov 12, 2025. The company had $77.0M in cash, cash equivalents and short-term investments as of Sep 30, 2025, which it expects will fund operations into 2027. Clinical progress includes a Phase 1a single ascending dose trial with initial data expected by year-end 2025 and a newly initiated Phase 1b/2 multiple ascending dose trial enrolling up to 80 nAMD patients with initial data expected in 2H 2026. Kalaris entered a formal CDMO agreement with KBI Biopharma, hired a new CFO, and opened headquarters in Berkeley Heights, NJ. Q3 net loss was $11.9M; shares outstanding were 18,702,418.
Kalaris (NASDAQ:KLRS) appointed Matthew Gall, MBA as Chief Financial Officer effective Nov 3, 2025.
The hire strengthens Kalaris’ leadership as the company enrolls its Phase 1b/2 study in treatment‑naïve nAMD patients. Gall previously served as CFO of iTeos Therapeutics and held finance and business development roles at Sarepta, Celgene, and Gilead. He holds a BS in Business Administration from Bowling Green State University and an MBA from The University of Chicago.
The company described the appointment as supporting capital strategy, business development and scaling during clinical advancement.
Kalaris (Nasdaq: KLRS) announced that company management will present at the Stifel 2025 Annual Healthcare Conference on Thursday, November 13, 2025 from 3:20–3:50pm ET at the Lotte New York Palace Hotel in New York, NY.
Speakers listed are Andrew Oxtoby, CEO, and Matthew Feinsod, CMO. Management will be available for one-on-one meetings during the conference; interested parties should contact their conference representative to arrange a meeting.
Kalaris Therapeutics (NASDAQ:KLRS) has begun enrolling patients in a Phase 1b/2 multiple ascending dose (MAD) study for TH103, targeting neovascular age-related macular degeneration (nAMD). The study will evaluate multiple dose levels in up to 80 nAMD patients, who will receive 4 monthly intravitreal injections.
The Phase 1b/2 study replaces a smaller Part 2 design and will inform dose selection for potential Phase 3 development. Initial data is expected in 2H 2026. Meanwhile, the ongoing Phase 1a single ascending dose study remains on schedule to report data in Q4 2025.
TH103, developed by Lasker Award recipient Dr. Napoleone Ferrara, represents a novel approach to treating exudative and neovascular retinal diseases, building on anti-VEGF therapy research.
Kalaris Therapeutics (NASDAQ:KLRS) has initiated enrollment for a Phase 1b/2 multiple ascending dose (MAD) study of TH103 in patients with neovascular age-related macular degeneration (nAMD). The study will evaluate up to 80 nAMD patients who will receive up to 4 monthly intravitreal injections of TH103.
The company expects to report initial data from the ongoing Phase 1a single ascending dose study in Q4 2025, with Phase 1b/2 data anticipated in 2H 2026. TH103, developed by Lasker Award recipient Dr. Napoleone Ferrara, represents a novel approach to treating exudative and neovascular retinal diseases, building on anti-VEGF therapy research.
Kalaris Therapeutics (NASDAQ:KLRS), a clinical-stage biopharmaceutical company focusing on retinal diseases, reported Q2 2025 financial results and provided business updates. The company continues enrolling patients in its Phase 1 trial of TH103, a novel anti-VEGF treatment for neovascular Age-related Macular Degeneration (nAMD), with initial clinical data expected in Q4 2025.
Financial highlights include cash position of $88.4 million as of June 30, 2025, expected to fund operations into Q4 2026. Q2 2025 resulted in a net loss of $11.4 million ($0.61 per share). The company strengthened its leadership team with the addition of Kristine Curtiss as SVP of Clinical, bringing 25 years of ophthalmology expertise.
FAQ
What is the current stock price of Kalaris Therapeutics (KLRS)?
What is the market cap of Kalaris Therapeutics (KLRS)?
